• Home
  • Leadership
    • Management Team
    • Scientific Advisory Board
  • Therapeutic Programs
  • Media
  • Contact
Potential Gene Therapy GENV-HEM Earns Orphan Drug Status

Potential Gene Therapy GENV-HEM Earns Orphan Drug Status

by Damon Race | Nov 3, 2021 | In the News

Hemophilia News Today by Marta Figueiredo PhD | November 3, 2021 The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GENV-HEM, GeneVentiv Therapeutics’ investigational gene therapy for hemophilia A and B patients, with or without...

Recent Posts

  • UNC-Chapel Hill gene therapy spinout raises $1.4 million
  • Bootstrapped UNC spinout lands $300K for gene therapy work
  • Triangle gene therapy startup GeneVentiv Therapeutics awarded $250K loan from NC Biotech Center
  • GeneVentiv Therapeutics Receives Funding from the North Carolina Biotechnology Center
  • GeneVentiv Therapeutics Wins KickStart Commercialization Grant

Recent Comments

    Archives

    • September 2022
    • June 2022
    • March 2022
    • February 2022
    • November 2021
    • March 2021
    • February 2021
    • January 2021
    • November 2020
    • October 2020

    Categories

    • In the News
    • Press

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    Contact Us

    • Please prove you are human by selecting the Car.
    • This field is for validation purposes and should be left unchanged.

    Copyright © 2020 GeneVentiv Therapeutics. All rights reserved.